S&P 500
6,005.88
+0.1%
+$5.52
DJI
42,761.76
-0.0%
-$1.11
NASDAQ
19,591.24
+0.3%
+$61.28
Bitcoin
109,637.00
+3.9%
+4,147.22
AAPL
$201.70
-1.1%
-$2.22
AMZN
$217.31
+1.8%
+$3.74
GOOG
$177.80
+1.8%
+$3.09
META
$694.90
-0.4%
-$2.81
MSFT
$472.66
+0.5%
+$2.28
NVDA
$142.74
+0.7%
+$1.02
TSLA
$308.41
+4.5%
+$13.27
NeuroSense Therapeutics (NASDAQ: NRSN)
$1.90
(6.1%)
$0.11
Price as of June 9, 2025, 4:00 p.m. ET
NeuroSense Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
NeuroSense Therapeutics Company Info
Neurosense Therapeutics Ltd. is a clinical-stage biotechnology company. The firm is focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. It is involved in the 2b/3 clinical trial using its product candidate, PrimeC in patients with ALS and also commencing research into other possible indications for the drug, including Alzheimer’s and Parkinson’s diseases. The company was founded by Alon Ben-Noon on February 13, 2017 and is headquartered in Herzliya, Israel.
News & Analysis
No articles found.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.